ArticleMolecules (Basel, Switzerland)2026
A Fluorescence-Based Acetylcholinesterase Inhibition Assay for Bioactivity-Guided Identification of Neuroactive Protoberberine Alkaloids from
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesThe identification of acetylcholinesterase (AChE) inhibitors from complex natural matrices remains challenging due to the limitations of conventional colorimetric assays. This study aimed to develop a fluorescence-based AChE inhibition assay (FAIA) suitable for screening plant extracts, while simultaneously characterizing the metabolite profile of
methodsMethanolic extracts of
resultsTwenty-five metabolites, including eight isoquinoline alkaloids, were tentatively identified in the fruit extract. The optimized FAIA enabled reliable evaluation of AChE inhibition without the limitations associated with chromogenic assays. Among the CPC fractions, fraction 7 exhibited the strongest inhibitory activity. LC-MS analysis revealed that this fraction was enriched in protoberberine alkaloids, including berberine, palmatine, jatrorrhizine, magnocurarine, and demethyleneberberine. Cytotoxicity studies demonstrated concentration-dependent effects of both the isolated fractions and the individual alkaloids, with differentiated and undifferentiated SH-SY5Y cells exhibiting distinct sensitivity profiles. At 200 µg/mL, cell viability ranged from approximately 20-40% in undifferentiated SH-SY5Y cells and from approximately 25-45% in differentiated SH-SY5Y cells, depending on the CPC fraction. Among the tested protoberberine alkaloids, demethyleneberberine exhibited the lowest cytotoxic effect, maintaining the highest viability of differentiated SH-SY5Y cells, followed by jatrorrhizine and berberine.
conclusionsThe proposed FAIA represents a sensitive and practical approach for screening AChE inhibitors in complex plant matrices. Combined with metabolomic profiling and CPC-based bioassay-guided fractionation, it enabled the identification of alkaloid-rich fractions of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.